ICUs are among the most expensive environments in healthcare, where small increases in ventilation time or length of stay materially affect annual expenditure.¹ When sedation is delivered without blood concentration measurement, dosing variability increases the likelihood of prolonged mechanical ventilation and delayed recovery, compounding inefficiency across thousands of patients every year.²

Without measurement, clinicians default toward caution. Deeper or longer infusion reduces the perceived risk of agitation or instability, but that clinical logic, repeated across millions of sedation episodes annually, embeds avoidable cost into critical care pathways.² Deep or prolonged sedation drives ICU delirium,³ which in turn extends hospitalisation, increases complication rates, and raises readmission risk. In the United States alone, the annual economic burden of delirium is estimated between $38 billion and $152 billion.⁴

Excess sedation also increases the risk of ventilator-associated pneumonia (VAP), a serious complication of prolonged mechanical ventilation. VAP independently increases ICU length of stay, antibiotic use, and mortality risk. In the United States, each episode of VAP is estimated to add approximately $40,000 in treatment costs.⁷ When multiplied across large ICU populations, these preventable complications represent a significant and recurring financial burden.

Ventilated patients require higher nurse-to-patient ratios, amplifying staffing intensity in already resource-limited environments.⁵ In procedural settings, the inability to confirm when propofol concentrations have fallen to safe levels results in cautious discharge timing, reducing daily throughput and constraining utilisation of high-demand endoscopy and ambulatory units.⁶

The cost of unmeasured sedation is not incidental, it is structural. It recurs every day, across every ventilated patient, in every ICU. Measurement does not introduce new spending; it addresses an embedded inefficiency within a high-cost pathway.

Even modest reductions in ventilation duration or ICU length of stay generate disproportionate savings given the fixed and variable cost structure of critical care.¹ At national scale, those gains are material, tens of millions annually in the UK, billions in addressable inefficiency in the United States.

The opportunity extends beyond ICU. The inability to monitor propofol continuously limits broader adoption of total intravenous anaesthesia as an alternative to inhaled anaesthetic gases, which currently account for approximately 5% of hospital carbon emissions.⁷ Reliable near-patient monitoring removes one of the principal barriers to scaling TIVA, supporting both patient outcomes and healthcare sustainability commitments.

By aligning drug delivery with objective concentration data, ProSed® improves throughput, reduces complication-related expenditure, and strengthens the clinical and financial case for precision sedation across critical care and ambulatory settings.